Abstract

Pharmacologic Ascorbate in Myeloma Treatment: Doses Matter

Highlights

  • Because myeloma cells are iron-rich, increasing iron export increased their resistance to pharmacologic ascorbate

  • Consistent with mechanistic understanding, extracellular H2O2 generated by pharmacologic ascorbate was necessary for efficacy (Chen et al, 2008; Parrow et al, 2013)

  • Given continued use of melphalan in myeloma management, melphalan complications, and the compelling melphalan-sparing described by Xia et al (Xia et al, 2017), it is worth advancing pharmacologic ascorbate + melphalan to phase I trials

Read more

Summary

Introduction

Because myeloma cells are iron-rich, increasing iron export increased their resistance to pharmacologic ascorbate. Animal model results showed that pharmacologic ascorbate was synergistic with melphalan, permitting a 5-fold dose reduction. Consistent with mechanistic understanding, extracellular H2O2 generated by pharmacologic ascorbate was necessary for efficacy (Chen et al, 2008; Parrow et al, 2013).

Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.